ArticleFrontiers in immunology2025
Extracellular matrix remodeling fibroblasts govern the tumor microenvironment disparity between adenomatous lesions and adenocarcinoma in gallbladder.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer.Biology direct · 2026Article
- New progress and clinical research translation of immune checkpoint inhibitors in systemic therapy of gallbladder cancer.Frontiers in immunology · 2026Review
- The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons.Frontiers in pharmacology · 2026Review
- Emerging hallmarks and the rise of complexities and heterogeneity of tumor.Biochemistry and biophysics reports · 2025Review
- DDX11 interacts with PARP1 to facilitate PARylation, thereby promoting gallbladder cancer progression and conferring gemcitabine resistance.Acta biochimica et biophysica Sinica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gallbladder cancer (GBC) is a highly lethal cancer with a poor prognosis. The adenoma-carcinoma sequence is a recognized model for GBC development, but its underlying mechanisms are not well understood. Methods: Human specimens were collected from Shengjing Hospital of China Medical University. Single-cell isolation and sequencing were conducted on cells from four GBC and four gallbladder adenomatous lesions (GBA) samples, and the raw gene expression matrices were analyzed using R software with the Seurat package. This included cell type annotation, differential gene expression analysis, functional enrichment, and gene set score calculation. Additional analyses such as protein-protein interaction network, immune infiltrate analysis, high-dimensional weighted gene co-expression network analysis, and cell-cell communication analysis were also performed. Results: The study revealed that epithelial-mesenchymal transition (EMT) plays a key role in the malignant transformation of epithelial cells from GBA to GBC. The immune landscape of GBC is predominantly immunosuppressive compared to the inflammatory environment within GBA. A specific subset of fibroblasts with extracellular matrix remodeling capabilities appears to be a major driver of the TME differences between GBC and GBA, potentially acting through COL1A2-mediated cell communication. Discussion: This work highlights the distinct roles of various cell types in the TME of GBA and GBC, and emphasizes the importance of understanding the mechanisms of malignant transformation from adenomatous lesion to carcinoma in the gallbladder. The findings pave the way for further research into the mechanisms underlying the adenoma-carcinoma sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.